Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Torii Pharmaceutical Co stock price, quote, forecast and news

4551.T
JP3635800000
887536

Price

3,650.00
Today +/-
-0.41
Today %
-1.77 %
P

Torii Pharmaceutical Co stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Torii Pharmaceutical Co stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Torii Pharmaceutical Co stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Torii Pharmaceutical Co stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Torii Pharmaceutical Co's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Torii Pharmaceutical Co Stock Price History

DateTorii Pharmaceutical Co Price
9/4/20243,650.00 undefined
9/3/20243,715.00 undefined
9/2/20243,645.00 undefined
8/30/20243,690.00 undefined
8/29/20243,690.00 undefined
8/28/20243,615.00 undefined
8/27/20243,550.00 undefined
8/26/20243,480.00 undefined
8/23/20243,440.00 undefined
8/22/20243,455.00 undefined
8/21/20243,425.00 undefined
8/20/20243,480.00 undefined
8/19/20243,420.00 undefined
8/16/20243,490.00 undefined
8/15/20243,455.00 undefined
8/14/20243,470.00 undefined
8/13/20243,495.00 undefined
8/9/20243,415.00 undefined
8/8/20243,380.00 undefined

Torii Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Torii Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Torii Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Torii Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Torii Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Torii Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Torii Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Torii Pharmaceutical Co’s growth potential.

Torii Pharmaceutical Co Revenue, EBIT and net profit per share

DateTorii Pharmaceutical Co RevenueTorii Pharmaceutical Co EBITTorii Pharmaceutical Co Net Income
2026e69.49 B undefined0 undefined6.62 B undefined
2025e64.56 B undefined0 undefined5.94 B undefined
2024e60.15 B undefined0 undefined4.95 B undefined
202354.64 B undefined5.04 B undefined4.12 B undefined
202248.9 B undefined5.54 B undefined3.94 B undefined
202146.99 B undefined4.66 B undefined3.37 B undefined
202041.7 B undefined4.74 B undefined3.5 B undefined
201943 B undefined1.43 B undefined27.37 B undefined
201862.55 B undefined4.95 B undefined1.16 B undefined
201764.14 B undefined6.28 B undefined4.72 B undefined
201660.21 B undefined3.82 B undefined2.84 B undefined
201562.38 B undefined4.92 B undefined3.53 B undefined
201443.5 B undefined4.03 B undefined2.42 B undefined
201358.11 B undefined4.99 B undefined3.35 B undefined
201252.29 B undefined2.79 B undefined1.85 B undefined
201148.72 B undefined4.15 B undefined2.61 B undefined
201045.33 B undefined1.85 B undefined937 M undefined
200942.41 B undefined6.13 B undefined3.64 B undefined
200837.35 B undefined4.9 B undefined3.48 B undefined
200740.84 B undefined5.11 B undefined2.97 B undefined
200639.58 B undefined5.3 B undefined3.03 B undefined
200540.48 B undefined7.53 B undefined4.15 B undefined
200441.91 B undefined8.45 B undefined5.77 B undefined

Torii Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
38.3338.0240.3545.0947.7845.9343.2442.3841.9140.4839.5840.8437.3542.4145.3348.7252.2958.1143.562.3860.2164.1462.554341.746.9948.954.6460.1564.5669.49
--0.836.1511.745.97-3.88-5.84-1.99-1.13-3.41-2.233.21-8.5613.566.887.467.3411.12-25.1343.38-3.486.53-2.47-31.26-3.0212.684.0611.7410.087.347.63
61.5462.5162.3564.7165.0163.8261.6862.4062.6362.9961.0360.1363.4662.3158.9757.8456.3254.8052.6850.6049.6951.2149.0951.8552.1351.8047.8245.37---
23.5923.7725.1629.1831.0729.3126.6726.4526.2425.4924.1524.5623.726.4326.7328.1829.4531.8422.9231.5629.9232.8430.7122.321.7424.3423.3824.79000
5.746.227.3710.1313.3110.328.7398.457.535.35.114.96.131.854.152.794.994.034.923.826.284.951.434.744.665.545.04000
14.9816.3618.2622.4727.8622.4620.1821.2420.1618.6013.3812.5113.1314.454.088.535.348.589.277.896.349.797.923.3311.369.9111.339.22---
2.642.963.355.365.464.894.284.895.774.153.032.973.483.640.942.611.853.352.423.532.844.721.1627.373.53.373.944.124.955.946.62
-12.1513.2059.801.98-10.60-12.4314.2618.04-28.02-27.09-2.0117.164.78-74.27178.66-29.1881.29-27.8345.80-19.5166.19-75.332,251.12-87.23-3.4616.894.4420.2719.8011.56
-------------------------------
-------------------------------
2929292929292929282828282828282828282828.328.2828.9828.0628.0728.0828.0928.128.1000
-------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Torii Pharmaceutical Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Torii Pharmaceutical Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (B)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (B)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (M)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
1996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                       
6.549.7511.3715.7323.2726.5228.530.4126.5319.1718.649.489.3416.8731.3536.3135.117.2119.5333.0733.531.4232.0938.9242.2542.2147.6944
12.9514.3415.8918.8918.9916.3416.4115.3115.3515.0815.0615.314.4716.4218.4419.5820.2424.1525.8927.926.5529.1127.1425.1418.9522.0122.8728.49
3.361.150.890.580.671.730.30.260.790.590.540.070.210.010.030.010.040.010.010.010.010.0100.010.01000.01
2.552.612.852.762.783.382.893.172.894.013.573.95.235.595.386.347.538.0310.149.8410.6110.138.317.517.158.768.9710.74
0.040.090.420.8710.825.347.2612.0720.1921.231.7135.0231.6313.378.118.5823.0616.566.359.4613.3210.9138.4328.3924.3112.084.9
25.4327.9531.4138.8446.7148.7853.4356.4157.6259.0358.9960.4564.2770.5268.5670.3571.4972.4772.1277.1680.1283.9878.45110.0296.7497.2991.688.15
14.5814.0614.1413.439.437.5776.615.856.36.456.846.346.35.675.35.655.775.816.185.755.543.432.781.782.082.282.1
0.680.80.680.620.691.191.381.6544.595.034.582.662.894.246.45.396.717.076.83.887.4813.7719.7620.8122.3130.2833.97
1952620710988676454225121000000000
0.060.060.110.320.60.750.680.890.860.981.110.910.680.670.680.70.640.620.820.960.90.820.670.530.440.510.520.43
0000000000000000000000000000
2.642.362.071.462.552.942.853.35.75.865.967.657.485.255.724.978.187.576.737.787.886.936.936.866.268.629.018.79
17.9717.817.215.8413.2712.4611.9212.4616.4117.7418.5419.9817.1515.1116.3217.3819.8620.6720.4321.7118.420.7624.829.9329.2833.5242.0945.28
43.445.7448.6254.6859.9961.2565.3568.8774.0376.7777.5380.4381.4285.6384.8787.7391.3593.1492.5598.8798.53104.74103.25139.94126.03130.81133.69133.43
                                                       
5.195.195.195.195.195.195.195.195.195.195.195.195.195.195.195.195.195.195.195.195.195.195.195.195.195.195.195.19
6.426.426.426.426.426.426.426.426.426.426.426.426.426.426.426.426.426.426.426.426.426.426.436.436.446.456.456.46
17.6720.0122.7428.6133.4437.6641.345.5350.6854.0456.3158.5461.1163.6563.464.8865.5967.8169.171.3872.8776.2576.07102.09104.23106.25108.85109.43
000000000000000-1,00001,0001,0001,00001,000001,0000-1,0001,000
000060094262240443528466172243100208358457377698558745864850636523117427
29.2831.6234.3540.2145.1149.265357.462.5266.0968.4470.6172.8975.575.176.6977.5679.8881.0983.6985.0388.688.55114.56116.5118.41120.61121.5
5.545.335.815.765.585.845.155.034.925.414.144.464.153.783.824.725.676.386.16.856.78.246.665.755.145.796.586.98
3.013.273.394.015.332.9831.692.051.611.881.921.92.12.212.212.022.051.771.371.381.481.50.830.690.810.750.93
2.613.072.963.193.112.483.254.514.393.362.843.272.063.853.564.296.134.713.195.915.046.066.0418.283.545.565.64.37
1.060.660.730.40.330.20.20.200000000000000000000
0000000000007742211514020133134219985858585211283222
12.2112.3212.8813.3614.3511.511.6111.4311.3610.378.869.658.189.769.6111.2313.9713.3411.3914.4713.3115.8714.2724.949.4612.3713.2212.5
00000000000051832217119338772557146538029420927524122
000000000000000000000029200000
1.911.81.391.110.530.490.750.870.991.161.081.031.161.220.990.650.610.590.550.851.091.291.511.581.271.1510.77
1.911.81.391.110.530.490.750.870.991.161.081.031.211.221.030.670.680.780.931.571.661.752.181.881.471.421.240.79
14.1214.1214.2714.4714.8811.9912.3612.3112.3611.549.9410.679.3910.9910.6311.914.6514.1212.3316.0414.9717.6216.4526.8210.9413.814.4713.3
43.445.7448.6254.6859.9961.2565.3669.774.8877.6278.3881.2882.2886.4885.7388.5992.219493.4199.73100106.22105141.37127.43132.2135.07134.8
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Torii Pharmaceutical Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Torii Pharmaceutical Co's financial health and stability.

Assets

Torii Pharmaceutical Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Torii Pharmaceutical Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Torii Pharmaceutical Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Torii Pharmaceutical Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199920002001200220032004200520062007200820092010201120122013null2014201520162017201820192020202120222023
9.9710.229.128.219.1610.127.545.435.386.046.341.845.052.935.135.133.785.264.066.373.0337.74.234.775.725.59
1.471.281.020.930.820.840.861.011.221.421.411.391.191.061.091.090.921.461.341.171.040.990.580.410.450.46
00000000000000000000000000
-6.39-5.68-4.59-3.08-4.03-6.27-5.08-2.94-2.99-3.89-2.56-3.63-3.07-3.68-6.31-6.31-5.6-1.54-1.88-1.172.2440.05-8.72-5.11-3.44-8.81
0.873.41.41-0.030.030.910.11-0.09-0.28-0.31-0.19-0.13-0.13-0.15-0.12-0.120.28-0.24-0.12-0.021.95-36.230.47-0.23-0.31-0.37
42111000011110000001000000
4.274.866.63.93.724.323.182.752.652.641.463.012.071.921.111.111.170.412.51.261.861.49.41-0.022.011.8
5.929.226.956.035.985.593.433.413.333.265-0.523.040.15-0.2-0.2-0.614.943.46.358.2642.5-3.44-0.162.42-3.12
-1,194-1,030-941-393-638-870-1,044-1,756-1,324-1,040-1,283-829-683-1,350-811-811-884-1,484-760-789-675-546-411-374-281-216
-2.19-1.99-4.515.05-3.72-4.330.11-3.440.820.23-10.4-21.33.150.8717.7117.710.50.961.36-7.59-27.072.17.63-1.5-13.68-3.78
-1-0.96-3.575.44-3.09-3.461.15-1.682.151.27-9.11-20.473.832.2218.5218.521.382.442.12-6.8-26.392.658.04-1.12-13.4-3.56
00000000000000000000000000
-300-100000-200000-82-77-53-21-48-185-185-277-334-315-198-85-85-85-198-348-293
0000-836-4-3-1-1-2-1-100-1-10-2-615-10-18000
-875-675-633-633-1,498-826-795-736-736-989-1,181-1,242-1,154-1,181-1,319-1,319-1,410-1,582-2,289-1,546-1,432-1,433-1,425-1,546-1,698-3,835
-------------1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00-1.00--1.00--2.00-2.00
-575-575-633-633-662-622-792-735-735-905-1,103-1,188-1,132-1,132-1,132-1,132-1,132-1,245-1,358-1,346-1,346-1,347-1,347-1,348-1,348-3,540
2.866.551.7510.440.760.442.74-0.763.422.5-6.58-23.065.04-0.1516.1916.19-1.524.322.48-2.79-20.2443.172.76-3.2-12.95-10.74
4,7308,1886,0135,6335,3414,7202,3811,6572,0072,2213,715-1,3472,358-1,197-1,0120-1,4933,4572,6435,5617,58441,953-3,855-5312,139-3,340
00000000000000000000000000

Torii Pharmaceutical Co stock margins

The Torii Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Torii Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Torii Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Torii Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Torii Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Torii Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Torii Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Torii Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Torii Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Torii Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Torii Pharmaceutical Co Margin History

Torii Pharmaceutical Co Gross marginTorii Pharmaceutical Co Profit marginTorii Pharmaceutical Co EBIT marginTorii Pharmaceutical Co Profit margin
2026e45.37 %0 %9.53 %
2025e45.37 %0 %9.19 %
2024e45.37 %0 %8.24 %
202345.37 %9.22 %7.54 %
202247.82 %11.33 %8.07 %
202151.8 %9.91 %7.18 %
202052.13 %11.36 %8.38 %
201951.85 %3.33 %63.65 %
201849.09 %7.92 %1.86 %
201751.21 %9.79 %7.36 %
201649.69 %6.34 %4.72 %
201550.6 %7.89 %5.65 %
201452.68 %9.27 %5.56 %
201354.8 %8.58 %5.77 %
201256.32 %5.34 %3.54 %
201157.84 %8.53 %5.36 %
201058.97 %4.08 %2.07 %
200962.31 %14.45 %8.59 %
200863.46 %13.13 %9.31 %
200760.13 %12.51 %7.26 %
200661.03 %13.38 %7.65 %
200562.99 %18.6 %10.26 %
200462.63 %20.16 %13.77 %

Torii Pharmaceutical Co Stock Sales Revenue, EBIT, Earnings per Share

The Torii Pharmaceutical Co earnings per share therefore indicates how much revenue Torii Pharmaceutical Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Torii Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Torii Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Torii Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Torii Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Torii Pharmaceutical Co Revenue, EBIT and net profit per share

DateTorii Pharmaceutical Co Sales per ShareTorii Pharmaceutical Co EBIT per shareTorii Pharmaceutical Co Earnings per Share
2026e2,471.87 undefined0 undefined235.53 undefined
2025e2,296.53 undefined0 undefined211.14 undefined
2024e2,139.55 undefined0 undefined176.25 undefined
20231,944.21 undefined179.16 undefined146.57 undefined
20221,740.32 undefined197.18 undefined140.38 undefined
20211,672.73 undefined165.75 undefined120.11 undefined
20201,484.99 undefined168.73 undefined124.46 undefined
20191,531.87 undefined50.95 undefined974.99 undefined
20182,229.43 undefined176.46 undefined41.49 undefined
20172,213.08 undefined216.74 undefined162.8 undefined
20162,128.7 undefined135.03 undefined100.38 undefined
20152,204.25 undefined173.82 undefined124.63 undefined
20141,553.71 undefined144 undefined86.39 undefined
20132,075.32 undefined178.11 undefined119.71 undefined
20121,867.64 undefined99.79 undefined66.04 undefined
20111,739.89 undefined148.36 undefined93.25 undefined
20101,619.07 undefined66.04 undefined33.46 undefined
20091,514.79 undefined218.82 undefined130.07 undefined
20081,333.86 undefined175.11 undefined124.14 undefined
20071,458.71 undefined182.43 undefined105.96 undefined
20061,413.39 undefined189.11 undefined108.14 undefined
20051,445.57 undefined268.89 undefined148.32 undefined
20041,496.64 undefined301.75 undefined206.07 undefined

Torii Pharmaceutical Co business model

Torii Pharmaceutical Co Ltd is a Japanese pharmaceutical company founded in 1921. The company is headquartered in Tokyo and employs over 1,200 employees. Torii specializes in the development and manufacturing of medicines for the treatment of diseases such as diabetes, cancer, kidney and liver diseases, as well as allergic diseases and mental disorders. The business model of Torii is based on developing and manufacturing innovative medicines that have a high benefit for patients. To achieve this, the company invests a large portion of its revenue in research and development of new drugs. The goal is to improve both the quality of life of patients and support society by creating new healing opportunities. Torii is divided into two business segments: Pharma and Nutraceuticals. In the Pharma segment, the company produces prescription drugs that are primarily sold in Japanese hospitals and clinics. On the other hand, the Nutraceutical division offers products that are sold without a prescription and focus on dietary supplements and health-promoting products. Torii has a wide range of products, ranging from various medications to dietary supplements and functional foods. One of Torii's most well-known products is an antidiabetic called "Trelagliptin". The medication is used to treat type 2 diabetes and is the best-selling diabetes medication in Japan. Another important product from Torii is "UFT™", a chemotherapy treatment for cancer. UFT™ is particularly effective in treating stomach, colon, and lung cancer. Another significant medication is "Micardis™", a blood pressure-lowering medication. The medication lowers blood pressure without unwanted side effects and is also available in Europe and the United States. In the Nutraceutical division, Torii offers various products such as vitamins, minerals, dietary supplements, functional foods, and beverages. One highlight is "Real Gold Three", a dietary supplement that contains eight valuable herbs and focuses on improving the immune system. The product is sold in both Japan and China. In recent years, the company has established strategic partnerships with various other companies to promote innovation and accelerate growth. In 2019, the company signed a collaboration agreement with the Vietnamese division of the British pharmaceutical giant GlaxoSmithKline (GSK). The goal of the collaboration is to strengthen the distribution of GSK products in the Vietnamese market. Torii sees itself not only as a pharmaceutical company but also as part of society. The company actively supports social projects and corporate social responsibility (CSR). For example, Torii supports the "Operation Smile" program, which aims to help children with cleft lips and palates. Overall, Torii is an important player in the Japanese pharmaceutical market specializing in research, development, and marketing of innovative medicines. The company has a broad portfolio and has expanded its product range in recent years with various high-quality products. With its partnerships and social initiatives, Torii demonstrates that it is not only a commercial company but also makes an important contribution to society and the health of people. Torii Pharmaceutical Co is one of the most popular companies on Eulerpool.com.

Torii Pharmaceutical Co SWOT Analysis

Strengths

  • Strong market presence: Torii Pharmaceutical Co Ltd has established itself as a leading player in the pharmaceutical industry, with a significant market share in several therapy areas.
  • Diverse product portfolio: The company offers a wide range of pharmaceutical products across various therapeutic categories, allowing it to cater to a diverse customer base and capture multiple revenue streams.
  • Robust research and development capabilities: Torii Pharmaceutical invests heavily in R&D, enabling it to continually develop innovative drugs and maintain a competitive edge in the market.

Weaknesses

  • Dependence on a few key products: Despite having a diverse product portfolio, the company relies heavily on a few key drugs for a significant portion of its revenue. This creates a vulnerability to competition and potential revenue fluctuations.
  • Limited international presence: Torii Pharmaceutical's market reach is primarily concentrated in Japan, limiting its exposure to potential growth opportunities in other global markets.

Opportunities

  • Expansion into emerging markets: The company can explore expansion opportunities in emerging markets, such as developing countries with growing healthcare sectors, to tap into untapped market potential.
  • Strategic partnerships and collaborations: Torii Pharmaceutical can consider forming strategic alliances with other pharmaceutical companies or research institutions to leverage combined expertise and accelerate the development of new drugs.

Threats

  • Intense competition: The pharmaceutical industry is highly competitive, with many established players and new entrants constantly entering the market. Torii Pharmaceutical needs to stay vigilant and innovative to stay ahead of the competition.
  • Stringent regulatory environment: The company operates in a heavily regulated industry, requiring strict compliance with various regulatory agencies. Any failure to meet these regulations could lead to delays in product launches or even legal consequences.

Torii Pharmaceutical Co Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Torii Pharmaceutical Co historical P/E ratio, EBIT, and P/S ratio.

Torii Pharmaceutical Co shares outstanding

The number of shares was Torii Pharmaceutical Co in 2023 — This indicates how many shares 28.103 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Torii Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Torii Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Torii Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Torii Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Torii Pharmaceutical Co Stock splits

In Torii Pharmaceutical Co's history, there have been no stock splits.

Torii Pharmaceutical Co dividend history and estimates

In 2023, Torii Pharmaceutical Co paid a dividend amounting to 120 JPY. Dividend means that Torii Pharmaceutical Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Torii Pharmaceutical Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Torii Pharmaceutical Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Torii Pharmaceutical Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Torii Pharmaceutical Co Dividend History

DateTorii Pharmaceutical Co Dividend
2026e121.83 undefined
2025e121.66 undefined
2024e121.84 undefined
2023120 undefined
2022100 undefined
202148 undefined
202048 undefined
201948 undefined
201848 undefined
201748 undefined
201648 undefined
201548 undefined
201460 undefined
201340 undefined
201240 undefined
201140 undefined
201042 undefined
200939 undefined
200832 undefined
200726 undefined
200626 undefined
200524 undefined
200422 undefined

Torii Pharmaceutical Co dividend payout ratio

In 2023, Torii Pharmaceutical Co had a payout ratio of 49.92%. The payout ratio indicates the percentage of the company's profits that Torii Pharmaceutical Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Torii Pharmaceutical Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Torii Pharmaceutical Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Torii Pharmaceutical Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Torii Pharmaceutical Co Payout Ratio History

DateTorii Pharmaceutical Co Payout ratio
2026e53.97 %
2025e58.29 %
2024e53.71 %
202349.92 %
202271.24 %
202139.96 %
202038.57 %
20194.92 %
2018115.7 %
201729.48 %
201647.82 %
201538.51 %
201469.45 %
201333.41 %
201260.58 %
201142.9 %
2010125.52 %
200929.98 %
200825.78 %
200724.54 %
200624.04 %
200516.18 %
200410.68 %
Unfortunately, there are currently no price targets and forecasts available for Torii Pharmaceutical Co.

Torii Pharmaceutical Co list of shareholders

%
Name
Stocks
Change
Date
54.78 % Japan Tobacco Inc15,398,80006/30/2023
5.97 % Effissimo Capital Management Pte. Ltd.1,677,00003/8/2024
3.95 % The Tachibana Securities Co., Ltd.1,109,000143,2006/30/2023
1.99 % Jefferies LLC560,00006/30/2023
1.51 % Zennor Asset Management LLP424,60039,5001/31/2024
1.12 % Nomura Asset Management Co., Ltd.315,1042,1003/31/2024
1.09 % The Vanguard Group, Inc.305,536-4,8003/31/2024
1.08 % Norges Bank Investment Management (NBIM)305,000122,2646/30/2023
1.03 % Amundi Japan Ltd.290,500192,4002/29/2024
0.86 % Monex Asset Management, Inc.242,27777,5503/31/2023
1
2
3
4
5
...
8

Most common questions regarding Torii Pharmaceutical Co

What values and corporate philosophy does Torii Pharmaceutical Co represent?

Torii Pharmaceutical Co Ltd represents values of excellence, integrity, and innovation. The company believes in delivering high-quality pharmaceutical products that improve the health and well-being of individuals. With a focus on research and development, Torii Pharmaceutical Co Ltd strives to provide innovative solutions and meet the changing needs of patients. The company's corporate philosophy emphasizes the importance of contributing to society through the development of safe and effective medications. By prioritizing patient-centric care, Torii Pharmaceutical Co Ltd aims to become a trusted partner in the global healthcare industry.

In which countries and regions is Torii Pharmaceutical Co primarily present?

Torii Pharmaceutical Co Ltd is primarily present in Japan.

What significant milestones has the company Torii Pharmaceutical Co achieved?

Since its establishment, Torii Pharmaceutical Co Ltd has reached several significant milestones. Notably, the company successfully launched its flagship product, Toubeauty®, an innovative skincare solution beloved by consumers worldwide. Torii Pharmaceutical Co Ltd also expanded its global presence by securing distribution agreements in key markets, further contributing to its growth and success. Additionally, the company has made strides in research and development, leading to the launch of groundbreaking pharmaceutical products that have positively impacted patients' lives. Overall, Torii Pharmaceutical Co Ltd continues to demonstrate its commitment to innovation, excellence, and improving the well-being of individuals through its remarkable achievements.

What is the history and background of the company Torii Pharmaceutical Co?

Torii Pharmaceutical Co Ltd is a renowned pharmaceutical company with a rich history and background. Founded in 1921, Torii Pharmaceutical has been providing innovative healthcare solutions for nearly a century. The company specializes in developing and manufacturing high-quality prescription drugs, over-the-counter medications, and healthcare products. With a strong emphasis on research and development, Torii Pharmaceutical has earned a reputation for its commitment to improving global health. Through strategic partnerships and collaborations, the company has expanded its global presence, delivering its products to diverse markets. Torii Pharmaceutical continues to strive for excellence, ensuring the well-being of individuals worldwide through cutting-edge pharmaceutical advancements.

Who are the main competitors of Torii Pharmaceutical Co in the market?

The main competitors of Torii Pharmaceutical Co Ltd in the market include companies such as Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co., Ltd., and Shionogi & Co., Ltd.

In which industries is Torii Pharmaceutical Co primarily active?

Torii Pharmaceutical Co Ltd is primarily active in the pharmaceutical industry.

What is the business model of Torii Pharmaceutical Co?

The business model of Torii Pharmaceutical Co Ltd revolves around the development, manufacturing, and sales of various pharmaceutical products. As a leading pharmaceutical company, Torii Pharmaceutical focuses on research and development to create innovative healthcare solutions. With a wide range of products spanning different therapeutic areas such as cardiovascular, respiratory, and central nervous system disorders, Torii Pharmaceutical aims to improve patient outcomes and enhance quality of life. Through strategic partnerships and collaborations, the company strives to expand its presence in both domestic and international markets, ensuring the delivery of high-quality and effective medications to patients worldwide.

What is the P/E ratio of Torii Pharmaceutical Co 2024?

The Torii Pharmaceutical Co P/E ratio is 20.7.

What is the P/S ratio of Torii Pharmaceutical Co 2024?

The Torii Pharmaceutical Co P/S ratio is 1.71.

What is the AlleAktien quality score of Torii Pharmaceutical Co?

The AlleAktien quality score for Torii Pharmaceutical Co is 4/10.

What is the revenue of Torii Pharmaceutical Co 2024?

The expected Torii Pharmaceutical Co revenue is 60.15 B JPY.

How high is the profit of Torii Pharmaceutical Co 2024?

The expected Torii Pharmaceutical Co profit is 4.95 B JPY.

What is the business model of Torii Pharmaceutical Co

Torii Pharmaceutical Co Ltd is a Japanese company specializing in the research, development, production, and marketing of pharmaceuticals. The company was founded in 1921 and is headquartered in Tokyo. The business model of Torii is based on developing and marketing innovative and effective drugs that contribute to improving the lives of patients. The company has a wide range of products in various therapy areas, such as cancer, cardiovascular diseases, metabolic disorders, immunology, and the nervous system. Torii operates in three main business areas: 1. Research and Development: Torii has an extensive research and development pipeline focused on novel drugs. The company invests heavily in the discovery and development of new pharmaceutical compounds and is constantly looking for promising technologies and therapies. 2. Manufacturing and Distribution: Torii has modern production facilities that meet the latest international standards to ensure that products are of high quality and safe. In addition, the company has an extensive distribution network in Japan and internationally to ensure that products can be delivered quickly and effectively to customers. 3. Brand Management: Torii markets and distributes its products under various brand names and is committed to raising awareness among the public and healthcare professionals. The company works closely with medical communities to maximize the effectiveness of its products and achieve broad market acceptance. Some of Torii's key products include: - Trelstar: A drug for the treatment of prostate cancer and endometriosis. - Edaravone: A neuroprotective drug for the treatment of amyotrophic lateral sclerosis (ALS). - Remitch: A drug for the treatment of sleep disorders. - Coniel: A drug for the treatment of hypertension. Torii also pursues a strategy of collaborating with other pharmaceutical companies to accelerate the development of new drugs and expand its global market presence. The company has already successfully formed partnerships with major international pharmaceutical companies such as Sanofi and Pfizer. Overall, Torii's business model aims to be a leading provider of pharmaceuticals that maintains a competitive position in the market through innovative technology, excellent product quality, and strong partnerships with other companies.

What is the Torii Pharmaceutical Co dividend?

Torii Pharmaceutical Co pays a dividend of 100 JPY distributed over payouts per year.

How often does Torii Pharmaceutical Co pay dividends?

The dividend cannot currently be calculated for Torii Pharmaceutical Co or the company does not pay out a dividend.

What is the Torii Pharmaceutical Co ISIN?

The ISIN of Torii Pharmaceutical Co is JP3635800000.

What is the Torii Pharmaceutical Co WKN?

The WKN of Torii Pharmaceutical Co is 887536.

What is the Torii Pharmaceutical Co ticker?

The ticker of Torii Pharmaceutical Co is 4551.T.

How much dividend does Torii Pharmaceutical Co pay?

Over the past 12 months, Torii Pharmaceutical Co paid a dividend of 120 JPY . This corresponds to a dividend yield of about 3.29 %. For the coming 12 months, Torii Pharmaceutical Co is expected to pay a dividend of 121.66 JPY.

What is the dividend yield of Torii Pharmaceutical Co?

The current dividend yield of Torii Pharmaceutical Co is 3.29 %.

When does Torii Pharmaceutical Co pay dividends?

Torii Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of July, January, July, January.

How secure is the dividend of Torii Pharmaceutical Co?

Torii Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Torii Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 121.66 JPY are expected. This corresponds to a dividend yield of 3.33 %.

In which sector is Torii Pharmaceutical Co located?

Torii Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Torii Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Torii Pharmaceutical Co from 3/1/2025 amounting to 60 JPY, you needed to have the stock in your portfolio before the ex-date on 12/27/2024.

When did Torii Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 3/1/2025.

What was the dividend of Torii Pharmaceutical Co in the year 2023?

In the year 2023, Torii Pharmaceutical Co distributed 100 JPY as dividends.

In which currency does Torii Pharmaceutical Co pay out the dividend?

The dividends of Torii Pharmaceutical Co are distributed in JPY.

All fundamentals about Torii Pharmaceutical Co

Our stock analysis for Torii Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Torii Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.